Progression of hemolysis in a patient with hereditary spherocytosis after the second dose of COVID-19 mRNA vaccine

Progression of hemolysis in a patient with hereditary spherocytosis after the second dose of COVID-19 mRNA vaccine

Herein, we report the case of a 22-year-old woman with hereditary spherocytosis (HS) whose condition worsened after administration of the coronavirus disease 2019 (COVID-19), mRNA vaccine ‘BNT162b2 Pfizer-BioNTech.’ The woman had been diagnosed with HS in 2005, and her condition remained stable unti...

Full description

Bibliographic Details
Main Authors: Jun Nomura, Masafumi Seki, Syori Abe, Tadahiro Kobayashi, Yoko Okitsu, Noriko Fukuhara, Shinichiro Takahashi, Hideo Harigae, Junichi Kameoka
Format: Article
Language:English
Published: Taylor & Francis Group 2023-01-01
Series:Human Vaccines & Immunotherapeutics
Subjects:
hereditary spherocytosis (hs)
mrna vaccine bnt162b2 ‘pfizer-biontech’
hemolysis
inflammatory cytokines
second vaccination
Online Access:http://dx.doi.org/10.1080/21645515.2023.2165381

Internet

http://dx.doi.org/10.1080/21645515.2023.2165381

Similar Items